What's hot in HealthVerity Marketplace: New sources expand what you can know
Most life sciences teams don't have a data shortage. They have blind spots such as patients who...
Topic
Marketplace
SDoH data for efficient, patient-centered clinical trials
The social determinants of health (SDoH) are a key component of understanding and delivering better...
The future of multiple sclerosis: Progression focused therapies and RWE
Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system (CNS)...
Mitigating data disruptions in open claims datasets
Healthcare data now accounts for approximately 30% of global data volume and with this surge in...
An integrated approach for deeper insight with both open and closed claims data
Pharma teams are under sharper financial scrutiny and policy pressure than they've been in years,...
Menopause at a turning point: RWD matters more than ever
A recent CNBC article used HealthVerity real-world data (RWD) to highlight a shortage of estrogen...
Subtler scopes: Where IRA drug negotiations meet Part D redesigns
Understanding how the IRA’s multiple provisions interact to induce cost-related change The...
TrOOPs: Tracking cost implications under IRA Part D reforms
As part of its many provisions, the Inflation Reduction Act (IRA) includes a dramatic...
Open claims vs. closed payer claims: What’s the difference?
Open claims and closed payer claims data are essential for understanding the status and activities...
Why RWE programs fail under regulatory scrutiny — and what leaders can do about it
FDA has made its expectations for RWE clearer and more structured through recent guidance and...